$-1.98
(Market cap
$2,434 Mln
Recently Viewed
Clear AllMarket cap
$2,434 Mln
Revenue (TTM)
$55 Mln
P/E Ratio
--
P/B Ratio
27.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-2.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-6.5
Debt to Equity
1.7
Book Value
$4.4
EPS
$-8.1
Face value
--
Shares outstanding
28,687,963
CFO
$-1,245.55 Mln
EBITDA
$-932.67 Mln
Net Profit
$-1,757.19 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
| 127.5 | 33.2 | 160.5 | 924.4 | 94.6 | -20.1 | -8.6 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
| 203.1 | 65.4 | -75.2 | -83.3 | -20.5 | -21.2 | -34.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
|
96.2 | 2,434.5 | 55.2 | -164.1 | -224.5 | -217.9 | -- | 27.1 |
| 13.6 | 4,437.3 | 3,018.8 | 72.1 | 12.6 | -80 | 63.2 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 185.3 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 74.3 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 45.9 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 13.0 | 10,903.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 17.9 | 2.7 | |
| 22.5 | 11,550.7 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.4 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 227.0 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune... system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California. Read more
CEO, President & Director
Mr. Howard W. Robin
CEO, President & Director
Mr. Howard W. Robin
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Nektar Therapeutics (NKTR) is $96.18 (NASDAQ) as of 22-Apr-2026 11:35 EDT. Nektar Therapeutics (NKTR) has given a return of 94.61% in the last 3 years.
Since, TTM earnings of Nektar Therapeutics (NKTR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.23
|
9.55
|
|
2024
|
-0.11
|
0.22
|
|
2023
|
-0.03
|
0.05
|
|
2022
|
-0.08
|
0.08
|
|
2021
|
-0.32
|
0.25
|
The 52-week high and low of Nektar Therapeutics (NKTR) are Rs 109.00 and Rs 7.99 as of 22-Apr-2026.
Nektar Therapeutics (NKTR) has a market capitalisation of $ 2,434 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nektar Therapeutics (NKTR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.